AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Semler Scientific under investigation by Faruqi & Faruqi for securities fraud.
ByAinvest
Wednesday, Oct 8, 2025 10:06 am ET1min read
Faruqi & Faruqi LLP is investigating potential claims against Semler Scientific, a biotechnology company. The investigation focuses on potential securities law violations between March 10, 2021, and April 15, 2025. Investors who suffered losses in Semler Scientific are encouraged to contact Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal rights. The deadline to seek the role of lead plaintiff is October 28, 2025.
Semler Scientific, Inc. (NASDAQ: SMLR), a biotechnology company, is facing a class action lawsuit alleging securities law violations. The lawsuit, filed on behalf of investors who purchased shares during the period from March 10, 2021, to April 15, 2025, accuses the company of making false and misleading statements and failing to disclose a material investigation by the U.S. Department of Justice (DOJ) into violations of the False Claims Act [2].The complaint alleges that Semler Scientific discussed potential violations of the False Claims Act in hypothetical terms without disclosing an ongoing DOJ investigation. The company's public statements were found to be false and materially misleading during the class period. The lawsuit claims that investors suffered damages as a result of these misrepresentations [2].
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Semler Scientific. The firm encourages investors who suffered losses to contact Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal rights [2].
The deadline to seek the role of lead plaintiff in the federal securities class action is October 28, 2025 [2]. Investors who purchased shares during the specified period are encouraged to contact the firm to discuss their participation in the lawsuit.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet